Current treatments

Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…

Complications of myeloma and its treatments

Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…

Biology and genetics

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…

Supportive treatments

Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…